Umoja Biopharma, a Seattle-based immunotherapy startup, has successfully raised $100 million in a Series C funding round aimed at advancing its in vivo CAR-T cell therapies. This funding round is notable as it marks the 10th 'megaround' of 2025, reflecting the growing interest in innovative cancer and autoimmune treatments. The company had previously announced a Series B funding round exceeding $175 million, indicating strong financial backing for its research and development efforts. Following this recent funding, Umoja Biopharma's valuation could reach approximately $700 million, as reported last week.